One particularly compelling strategy involves caveolin-derived peptides, such as Cavtratin, a Caveolin-1 scaffolding domain peptide, which has demonstrated potential in mitigating endothelial dysfunction and attenuating inflammation in cardiovascular and metabolic diseases. This evidence concerns the gene CAV1 and Other metabolic disease.